SDIX, a developer of antibody-based solutions, has introduced a new polyclonal antisera - Apo B - for the in vitro diagnostic (IVD) market.
Apo B, which is available as antisera and in fractionated forms, can be customized to various automated immunoassay platforms.
Factors such as detection limit, sensitivity, linearity and antigen excess (prozone) can be adjusted and controlled
SDIX IVD product manager Paul Dany said reagent quality and lot-to-lot consistency can be overcome by using SDIX customized reagent.
SDIX develops antigens, antibodies and assays for the pharmaceutical, biotechnology and food safety markets.